AstraZeneca Shares Tumble 7% After Reported Bristol Myers Talks: Reuters

AstraZeneca’s shares slide 7% after reports of Bristol Myers talks

Investors and analysts said Britain's biggest drugmaker had little obvious need for a transformative acquisition, despite the potential financial benefits.

AstraZeneca and Bristol Myers Squibb reported to have held talks over £300billion merger

Any deal would face major regulatory hurdles.

AstraZeneca shares drop on reports of $570b mega-merger

AstraZeneca has held talks with US rival Bristol Myers Squibb over a merger which could create a drugs giant worth almost $US400 billion, according to reports.

AstraZeneca shares fall on Bristol Myers Squibb merger talks

While a deal would create one of the world’s biggest pharmaceutical groups, it could lead to regulatory hurdles in the US under the Trump administration

AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb

The companies have discussed a potential merger over several months, the Financial Times reported on Sunday.

AstraZeneca shares tumble 7% after reported Bristol Myers talks

AstraZeneca shares tumbled 7% in early ​trading on Monday following reports of ‌talks between the European pharmaceutical giant and U.S.-based Bristol Myers Squibb , baffling investors and analysts.